PixCell Medical opens US subsidiary in Denver

PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, has opened a United States subsidiary in the Denver metropolitan area.

The new office aims to increase logistical and commercial support for PixCell’s U.S. clients and will handle order fulfilment across the country, as well as provide additional clinical and technical support to customers.

Dr. Avishay Bransky, co-founder and CEO of PixCell Medical, said: “Opening a U.S. office is a significant milestone for PixCell as we continue to expand access to HemoScreen around the world. We are already supplying units across Australia, Europe, and the U.S. to ensure that healthcare organizations can deliver lab-quality blood testing anywhere, in a timely and affordable manner. This office will allow us to better serve our growing customer base in the United States with technical, clinical and logistical support.”

PixCell’s HemoScreen is the only five-part differential CBC analyser that is both FDA-cleared and CE-marked for point-of-care use. The portable diagnostic device delivers lab-accurate results within five minutes. Utilising a patented, disposable cartridge preloaded with all necessary reagents, HemoScreen reduces reagent waste and eliminates the need for routine maintenance. With just one drop of blood, HemoScreen provides Complete Blood Count (CBC) results with 20 standard parameters, as well as comprehensive abnormal cell flagging for earlier detection of infection and certain cancer types.

Ned Imbrie, BD manager of PixCell’s U.S. subsidiary, said: “Just as HemoScreen offers near-patient blood testing, we are now offering localised support for our instrument. Decentralising blood testing from large industrial labs to the point of care has significant benefits to patients, healthcare providers, and the larger healthcare system that gets bogged down by this routine, yet resource-heavy test. Expanding our local U.S. presence will help us drive the transition within the healthcare system from traditional blood testing practices to the technologically advanced and efficient HemoScreen.”